| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/27/2011 | US20110020451 Tamper-resistant dosage form for oxidation-sensitive opioids |
| 01/27/2011 | US20110020450 Titratable dosage transdermal delivery system |
| 01/27/2011 | US20110020447 Novel dosage form |
| 01/27/2011 | US20110020446 Methods and formulations for making pharmaceutical compositions containing bupropion |
| 01/27/2011 | US20110020445 Extended release pharmaceutical compositions of levetiracetam |
| 01/27/2011 | US20110020444 Abuse-resistant opioid dosage form |
| 01/27/2011 | US20110020439 Delayed release compositions of duloxetine |
| 01/27/2011 | US20110020433 Compositions for delivery of cargo such as drugs proteins and/or genetic materials |
| 01/27/2011 | US20110020423 Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| 01/27/2011 | US20110020411 Factor replacement therapy |
| 01/27/2011 | US20110020407 Transdermal therapeutic system with high rate of utilization of active substance and dosing accuracy |
| 01/27/2011 | US20110020400 Probiotic bifidobacterium strains |
| 01/27/2011 | US20110020392 Process for treatment of rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis and non-viral based cancers |
| 01/27/2011 | US20110020377 Aminopyrimidines useful as inhibitors of protein kinases |
| 01/27/2011 | US20110020376 Aminopyrimidines useful as inhibitors of protein kinases |
| 01/27/2011 | US20110020370 Slc7a5 directed diagnostics and therapeutics for neoplastic disease |
| 01/27/2011 | US20110020359 Methods and compositions for treating neuronal damage or degeneration |
| 01/27/2011 | US20110020354 G-protein coupled receptor ligands and methods |
| 01/27/2011 | US20110020352 Endogenous retroviruses up-regulated in prostate cancer |
| 01/27/2011 | US20110020338 5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes |
| 01/27/2011 | US20110020313 Method of using and establishing an absorption rate level and a neuron firing level |
| 01/27/2011 | US20110020311 Therapy of multiple sclerosis, inflammatory neurological diseases and neurodegenerative diseases with 5'-deoxyadenosylcobalamin, growth hormone, immunomodulators, interleukins, other therapeutic agents, and physiotherapy |
| 01/27/2011 | US20110020309 Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergice disease |
| 01/27/2011 | US20110020301 Use of s-adenosylmethionine (sam) and superoxide dismutase (sod) for the preparation of medicaments for the treatment of alzheimer's disease |
| 01/27/2011 | US20110020300 Compositions and methods for inhibiting expression of glucocorticoid receptor (gcr) genes |
| 01/27/2011 | US20110020284 Probiotic bifidobacterium strains |
| 01/27/2011 | US20110020279 Rabies cure |
| 01/27/2011 | US20110020273 Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof |
| 01/27/2011 | US20110020268 Agent comprising g-csf for treatment of traumatic peripheral nerve injury and method for treating traumatic peripheral nerve injury with the same |
| 01/27/2011 | US20110020237 Compositions and Methods for Inhibiting Drusen Formation and for Diagnosing or Treating Drusen-Related Disorders |
| 01/27/2011 | US20110020227 Polysaccharide-containing block copolmer particles and uses thereof |
| 01/27/2011 | CA2804215A1 Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| 01/27/2011 | CA2775443A1 Methods of treating and preventing/reducing the likelihood of mesial temporal lobe epilepsy (tle) |
| 01/27/2011 | CA2770517A1 Cyclosporin conjugates |
| 01/27/2011 | CA2769474A1 Acyl guanidine derivatives modulating the hedgehog protein signaling pathway |
| 01/27/2011 | CA2768980A1 Oxazine derivatives and their use as bace inhibitors for the treatment of neurological disorders |
| 01/27/2011 | CA2768963A1 Compounds, compositions and methods for protecting brain health in neurodegenerative disorders |
| 01/27/2011 | CA2768881A1 Fused aminodihydropyrimidone derivatives |
| 01/27/2011 | CA2768832A1 Substituted benzoimidazolesulfonamides and substituted indolesulfonamides as mglur4 potentiators |
| 01/27/2011 | CA2768710A1 Combinations of curcuminoids and mtor inhibitors for the treatment of tauopathies |
| 01/27/2011 | CA2768668A1 Galantamine amino acid and peptide prodrugs and uses thereof |
| 01/27/2011 | CA2768392A1 Oligomer-opioid agonist conjugates |
| 01/27/2011 | CA2768333A1 1h-quinazoline-2, 4 -diones for use in the treatment of neuronal ceroid lipofuscinosis |
| 01/26/2011 | EP2278010A1 Streptococcus pneumoniae proteins and nucleic acids |
| 01/26/2011 | EP2278009A1 Streptococcus pneumoniae proteins and nucleic acids |
| 01/26/2011 | EP2278008A2 Streptococcus pneumoniae proteins and nucleic acids |
| 01/26/2011 | EP2278004A1 RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| 01/26/2011 | EP2277900A1 Metastin derivative and use thereof |
| 01/26/2011 | EP2277876A1 Substituted pyrimidines for the treatment of cancer |
| 01/26/2011 | EP2277863A1 Piperidine derivatives, process for their preparation and pharmaceutical compositions containing them |
| 01/26/2011 | EP2277861A1 Cyclic amine-1-carboxylic acid ester derivative and pharmaceutical composition containing the same |
| 01/26/2011 | EP2277857A2 New crystalline form V of agomelatine, method of preparing same and pharmaceutical compositions containing same |
| 01/26/2011 | EP2277850A1 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists |
| 01/26/2011 | EP2277552A1 Mnk kinase proteins and diabetes |
| 01/26/2011 | EP2277549A2 Therapeutic polyanhydride compounds for drug delivery |
| 01/26/2011 | EP2277531A1 Treatment of cns damage |
| 01/26/2011 | EP2277529A1 Therapeutical application of SCF |
| 01/26/2011 | EP2277526A1 Pharmaceutical composition with tetrahydroisohumulone |
| 01/26/2011 | EP2277521A1 Tamper-resitant oral opioid agonist formulations |
| 01/26/2011 | EP2277520A2 A pharmaceutical composition for angiotensin ii-mediated diseases |
| 01/26/2011 | EP2277518A1 Use of silymarin and silybin in the treatment of neural injury |
| 01/26/2011 | EP2277515A1 Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis |
| 01/26/2011 | EP2276769A1 New peptidomimetic compounds |
| 01/26/2011 | EP2276759A1 3-indazolyl-4-pyridylisothiazoles |
| 01/26/2011 | EP2276758A1 Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,3] oxadiazol-5-yl]-3-nit robenzene-1, 2-diol |
| 01/26/2011 | EP2276757A2 Macrocyclic compounds and methods of treatment |
| 01/26/2011 | EP2276741A1 Isoquinolinone derivatives as nk3 antagonists |
| 01/26/2011 | EP2276738A1 Ether benzylidene piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors |
| 01/26/2011 | EP2276737A1 4- [3- (aryloxy) benzylidene]-3-methyl piperidine aryl carboxamide compounds useful as faah inhibitors |
| 01/26/2011 | EP2276736A1 4- [3- (aryloxy) benzyliden]-3-methyl piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors |
| 01/26/2011 | EP2276735A1 Ether benzylidene piperidine aryl carboxamide compounds useful as faah inhibitors |
| 01/26/2011 | EP2276734A1 4-benzylidene-3-methylpiperidine aryl carboxamide compounds useful as faah inhibitors |
| 01/26/2011 | EP2276731A1 2-sulfonylamino-4-heteroaryl butyramide antagonists of ccr10 |
| 01/26/2011 | EP2276726A1 Compounds for lysosomal modulation and methods of use |
| 01/26/2011 | EP2276722A2 Polymorphic form of an aminoindan mesylate derivative |
| 01/26/2011 | EP2276502A1 Compositions for the prevention and treatment of neuroinjury and methods of use thereof |
| 01/26/2011 | EP2276494A1 Stable aqueous compositions comprising bioactive creatine species |
| 01/26/2011 | EP2276493A1 Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 |
| 01/26/2011 | EP2276485A1 Use of epothelone d in treating tau-associated diseases including alzheimer's disease |
| 01/26/2011 | EP2276482A2 Hsp90 inhibitors or modulators for treatment or prevention of substance-related disorders |
| 01/26/2011 | EP2276481A1 Use of benzo-fused heterocycle sulfamide derivatives for the treatment of anxiety |
| 01/26/2011 | EP2203439B1 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-ý1, 4'¨bipyridinyl-2'-ones |
| 01/26/2011 | EP2155740B1 Hetarylanilines as modulators for amyloid beta |
| 01/26/2011 | EP2081907B1 Aryl piperazine derivatives useful for the treatment of neuropsychiatry disorders |
| 01/26/2011 | EP2044029B1 Tartrate salt of (7s)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2r)-2-methylpiperazin-1-yl]-6,7-dihydro-5h-cyclopenta[b]pyridine |
| 01/26/2011 | EP1904029B1 Oral, quickly disintegrating film, which cannot be spit out, containing olanzapin |
| 01/26/2011 | EP1831173B1 Tetrahydroisoquinoline compounds for treatment of cns disorders |
| 01/26/2011 | EP1725261B1 Use of agonists and antagonists of interleukin-33 (il-33) |
| 01/26/2011 | EP1633733B1 Cannabinoid derivatives, methods of making, and use thereof |
| 01/26/2011 | EP1581490B1 Substituted 5-aminomethyl-1h-pyrrole-2-carboxamides |
| 01/26/2011 | EP1556489B1 Pharmaceutical composition for preparing a medicine for treating and/or preventing a pathology related to an obsessive behaviour or obesity |
| 01/26/2011 | EP1496892B1 1h-benzo(f)indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
| 01/26/2011 | CN1918128B Fused ring 4-oxopyrimidine derivative |
| 01/26/2011 | CN1872063B Microspheres or composition in use for long acting injection of Nalmefene or its salt, and preparation method |
| 01/26/2011 | CN101959899A New compound derived from germinated brown rice, and agent containing said compound as an active ingredient for prevention or amelioration of neuropathy |
| 01/26/2011 | CN101959893A Substituted arylamide oxazepinopyrimidone derivatives |
| 01/26/2011 | CN101959888A Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloal kanes |
| 01/26/2011 | CN101959886A Imidazo[1,2-a]pyridine-2-carboxamide derivatives, preparation thereof and application thereof in therapeutics |
| 01/26/2011 | CN101959885A Derivatives of N-heterocyclic-6-heterocyclic-imidazo[l,2- a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof |
| 01/26/2011 | CN101959883A 3-indazolyl-4-pyridylisothiazoles |